文献速递间质性肺疾病

纤维化间质性肺疾病精准医学的曙光

The Dawn of Precision Medicine in Fibrotic Interstitial Lung Disease.
PubMed 文献 · Chest · 2024-11-08

本文综述了纤维化间质性肺疾病(ILD)精准医学的进展。研究发现多种生物标志物可识别疾病易感性、辅助诊断、预测进展或评估治疗反应,并识别出可区分不同纤维化ILD或不同病程患者的内型,特定化合物仅对特定内型有效。然而,基础设施、财务、监管和伦理挑战阻碍了精准医学的临床实施。

要点

  • 生物标志物可识别纤维化ILD进展风险并指导治疗。
  • 内型可区分不同纤维化ILD或不同病程患者。
  • 特定化合物仅对特定内型有效,需精准匹配。

核心结论

  • 纤维化ILD精准医学取得实质性进展,但临床实施仍面临基础设施、财务、监管和伦理挑战。

研究设计与样本

  • 本文为综述,检索范围未明确报告。

主要发现

  • 已识别多种生物标志物,可突出疾病易感性风险、提供准确诊断、预测预后或评估治疗反应。
  • 精准医学进展识别出内型,可区分不同纤维化ILD患者或不同病程患者。
  • 近期研究显示特定化合物仅对特定内型有效。

关键数值与推荐

  • 抗纤维化治疗对除IPF外表现为进展性肺纤维化(PPF)的纤维化ILD有益。
  • 预测哪些纤维化ILD患者将表现为PPF仍具挑战性。

临床怎么用

  • 精准医学方法可识别进展风险患者,指导IPF或PPF患者的治疗。
  • 从一刀切方法转向以患者为中心的护理可能显著改善生活质量和生存。

局限性

  • 精准医学在临床实践中的实施仍未满足需求。
  • 基础设施、财务、监管和伦理挑战依然存在。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

TOPIC IMPORTANCE: Interstitial lung diseases (ILDs) represent a broad group of heterogeneous parenchymal lung diseases. Some ILDs progress, causing architectural distortion and pulmonary fibrosis, and thus are called fibrotic ILDs. Recent studies have shown a beneficial effect of antifibrotic therapy in fibrotic ILDs other than idiopathic pulmonary fibrosis (IPF) that manifest progressive pulmonary fibrosis (PPF). However, it remains challenging to predict which patients with fibrotic ILDs will demonstrate PPF. Precision medicine approaches could identify patients at risk for progression and guide treatment in patients with IPF or PPF. REVIEW FINDINGS: Multiple biomarkers able to highlight disease susceptibility risk, to provide an accurate diagnosis, and to prognosticate or assess treatment response have been identified. Advances in precision medicine led to the identification of endotypes that could discriminate patients with different fibrotic ILDs or patients with different disease courses. Importantly, recent studies have shown that particular compounds were efficacious only in particular endotypes. The aforementioned findings are promising. However, implementation in clinical practice remains an unmet need. SUMMARY: Substantial progress has been observed in the context of precision medicine approaches in fibrotic ILDs in recent years. Nonetheless, infrastructure, financial, regulatory, and ethical challenges remain before precision medicine can be implemented in clinical practice. Overcoming such barriers and moving from a one-size-fits-all approach to patient-centered care could improve patient quality of life and survival substantially.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Karampitsakos T, Tourki B, Herazo-Maya JD, et al. The Dawn of Precision Medicine in Fibrotic Interstitial Lung Disease. Chest. 2024. PMID: 39521375. doi:10.1016/j.chest.2024.10.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。